Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:07 pm Sale |
2024-12-31 | 13G | 89bio, Inc. ETNB |
BIOTECHNOLOGY VALUE FUND L P | 4,333,885 3.600% |
-2,477,746 (-36.38%) |
Filing History |
| 2025-02-14 4:05 pm Purchase |
2024-12-31 | 13G | Cidara Therapeutics, Inc. CDTX |
BIOTECHNOLOGY VALUE FUND L P | 1,093,499 9.990% |
390,373 (+55.52%) |
Filing History |
| 2025-02-14 4:02 pm Purchase |
2024-12-31 | 13G | Avalo Therapeutics, Inc. AVTX |
BIOTECHNOLOGY VALUE FUND L P | 1,038,542 9.990% |
71,243 (+7.37%) |
Filing History |
| 2025-02-04 8:09 pm Purchase |
2025-01-27 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 5,912,554 7.500% |
2,504,500 (+73.49%) |
Filing History |
| 2025-02-04 8:05 pm Sale |
2024-12-31 | 13G | Kura Oncology, Inc. KURA |
BIOTECHNOLOGY VALUE FUND L P | 3,408,054 4.300% |
-804,292 (-19.09%) |
Filing History |
| 2025-01-31 6:43 pm Purchase |
2025-01-24 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BIOTECHNOLOGY VALUE FUND L P | 4,393,210 7.200% |
4,393,210 (New Position) |
Filing History |
| 2025-01-29 5:12 pm Sale |
2025-01-27 | 13G | enGene Holdings Inc. Common Stock ENGN |
BIOTECHNOLOGY VALUE FUND L P | 945,402 1.800% |
-2,106,037 (-69.02%) |
Filing History |
| 2025-01-29 5:09 pm Sale |
2024-12-31 | 13G | enGene Holdings Inc. Common Stock ENGN |
BIOTECHNOLOGY VALUE FUND L P | 3,051,439 5.900% |
-145,000 (-4.54%) |
Filing History |
| 2025-01-28 5:19 pm Sale |
2025-01-24 | 13D | XOMA Corporation XOMA |
BIOTECHNOLOGY VALUE FUND L P | 2,983,026 25.300% |
-650,717 (-17.91%) |
Filing History |
| 2025-01-06 6:38 pm Purchase |
2024-12-27 | 13G | RAPT Therapeutics, Inc. RAPT |
BIOTECHNOLOGY VALUE FUND L P | 11,764,000 8.700% |
11,764,000 (New Position) |
Filing History |
| 2024-12-23 9:25 pm Unchanged |
2024-12-19 | 13D | Inventiva S.A. IVA |
BIOTECHNOLOGY VALUE FUND L P | 8,545,499 9.000% |
0 (Unchanged) |
Filing History |
| 2024-12-17 5:42 pm Purchase |
2024-12-13 | 13G | Palvella Therapeutics, Inc. PVLA |
BIOTECHNOLOGY VALUE FUND L P | 1,168,117 9.990% |
1,168,117 (New Position) |
Filing History |
| 2024-12-04 7:49 pm Sale |
2024-12-04 | 13D | Olema Pharmaceuticals, Inc. OLMA |
BIOTECHNOLOGY VALUE FUND L P | 7,557,237 9.990% |
-1,578,656 (-17.28%) |
Filing History |
| 2024-11-21 8:27 pm Purchase |
2024-11-14 | 13G | iTeos Therapeutics, Inc. ITOS |
BIOTECHNOLOGY VALUE FUND L P | 2,325,000 6.400% |
1,065,524 (+84.60%) |
Filing History |
| 2024-11-18 5:23 pm Purchase |
2024-11-11 | 13G | Verve Therapeutics, Inc. VERV |
BIOTECHNOLOGY VALUE FUND L P | 6,904,050 8.200% |
6,904,050 (New Position) |
Filing History |
| 2024-11-14 4:40 pm Purchase |
2024-09-30 | 13G | TScan Therapeutics, Inc. TCRX |
BIOTECHNOLOGY VALUE FUND L P | 5,073,003 9.990% |
658,093 (+14.91%) |
Filing History |
| 2024-11-14 4:39 pm Sale |
2024-09-30 | 13G | Ovid Therapeutics Inc. OVID |
BIOTECHNOLOGY VALUE FUND L P | 3,853,818 5.400% |
-2,997,233 (-43.75%) |
Filing History |
| 2024-11-14 4:38 pm Purchase |
2024-09-30 | 13G | Verastem, Inc. VSTM |
BIOTECHNOLOGY VALUE FUND L P | 4,279,521 9.990% |
1,662,119 (+63.50%) |
Filing History |
| 2024-11-14 4:37 pm Purchase |
2024-09-30 | 13G | Molecular Templates, Inc. MTEM |
BIOTECHNOLOGY VALUE FUND L P | 672,767 9.990% |
135,341 (+25.18%) |
Filing History |
| 2024-11-14 4:37 pm Sale |
2024-09-30 | 13G | Mirum Pharmaceuticals, Inc. MIRM |
BIOTECHNOLOGY VALUE FUND L P | 3,075,907 6.400% |
-1,294,117 (-29.61%) |
Filing History |